A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD

Summary

A study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older with mild cognitive impairment and mild-to-moderate to Alzheimer's disease.

Timeline

Start

2022-03-25

Primary completion

2024-01-15

Completion

2024-01-15

Publications

• Weinberg MS, Kodali MC, Li Z, Galler JA, Tidball AR, Reynolds WC, Young C, Devitte-McKee K, Fatima HA, Kivisakk P, Chatterjee M, Kulkarni A, Billingsly JM, Bartlett AL, Sui SH, Kuhtreiber WM, Gerber J, McManus AJ, Tanzi RE, Das S, Faustman DL, Arnold SE. Bacillus Calmette-Guerin (BCG) immunotherapy reprograms CNS immunity and alters Alzheimer's biomarkers: results from two open-label clinical trials. Commun Med (Lond). 2026 Jul 2;6(1):358. doi: 10.1038/s43856-026-01691-7.

Drugs

Indications